<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38180084</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1550-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>212</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of immunology (Baltimore, Md. : 1950)</Title><ISOAbbreviation>J Immunol</ISOAbbreviation></Journal><ArticleTitle>Antiviral and Anti-Inflammatory Therapeutic Effect of RAGE-Ig Protein against Multiple SARS-CoV-2 Variants of Concern Demonstrated in K18-hACE2 Mouse and Syrian Golden Hamster Models.</ArticleTitle><Pagination><StartPage>576</StartPage><EndPage>585</EndPage><MedlinePgn>576-585</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.2300392</ELocationID><Abstract><AbstractText>SARS-CoV-2 variants of concern (VOCs) continue to evolve and reemerge with chronic inflammatory long COVID sequelae, necessitating the development of anti-inflammatory therapeutic molecules. Therapeutic effects of the receptor for advanced glycation end products (RAGE) were reported in many inflammatory diseases. However, a therapeutic effect of RAGE in COVID-19 has not been reported. In the present study, we investigated whether and how the RAGE-Ig fusion protein would have an antiviral and anti-inflammatory therapeutic effect in the COVID-19 system. The protective therapeutic effect of RAGE-Ig was determined in&#xa0;vivo in K18-hACE2 transgenic mice and Syrian golden hamsters infected with six VOCs of SARS-CoV-2. The underlying antiviral mechanism of RAGE-Ig was determined in&#xa0;vitro in SARS-CoV-2-infected human lung epithelial cells (BEAS-2B). Following treatment of K18-hACE2 mice and hamsters infected with various SARS-CoV-2 VOCs with RAGE-Ig, we demonstrated (1) significant dose-dependent protection (i.e., greater survival, less weight loss, lower virus replication in the lungs); (2) a reduction of inflammatory macrophages (F4/80+/Ly6C+) and neutrophils (CD11b+/Ly6G+) infiltrating the infected lungs; (3) a RAGE-Ig dose-dependent increase in the expression of type I IFNs (IFN-&#x3b1; and IFN-&#x3b2;) and type III IFN (IFN&#x3bb;2) and a decrease in the inflammatory cytokines (IL-6 and IL-8) in SARS-CoV-2-infected human lung epithelial cells; and (4) a dose-dependent decrease in the expression of CD64 (FcgR1) on monocytes and lung epithelial cells from symptomatic COVID-19 patients. Our preclinical findings revealed type I and III IFN-mediated antiviral and anti-inflammatory therapeutic effects of RAGE-Ig protein against COVID-19 caused by multiple SARS-CoV-2 VOCs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by The American Association of Immunologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhanushkodi</LastName><ForeName>Nisha Rajeswari</ForeName><Initials>NR</Initials><Identifier Source="ORCID">0000-0001-8184-4050</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Swayam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3986-890X</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quadiri</LastName><ForeName>Afshana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0212-5854</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zayou</LastName><ForeName>Latifa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Ruchi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaik</LastName><ForeName>Amin Mohammed</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-4563-1749</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzer</LastName><ForeName>Berfin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4447-5385</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibraim</LastName><ForeName>Izabela Coimbra</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>High Containment Facility, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landucci</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>High Containment Facility, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tifrea</LastName><ForeName>Delia F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Irvine School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4649-8572</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamal</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-9145-382X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Irvine School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahed</LastName><ForeName>Hawa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Galactica Pharmaceuticals, Inc., Villanova, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>BenMohamed</LastName><ForeName>Lbachir</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology &amp; Biochemistry, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Immunology, University of California, Irvine, School of Medicine, Irvine, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI158060</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI150091</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI143348</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI147499</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI143326</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI138764</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI124911</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI110902</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>AI174383</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Immunol</MedlineTA><NlmUniqueID>2985117R</NlmUniqueID><ISSNLinking>0022-1767</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067759">Receptor for Advanced Glycation End Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C045927">K-18 conjugate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005719">gamma-Globulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q41OR9510P</RegistryNumber><NameOfSubstance UI="D008558">Melphalan</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008647" MajorTopicYN="N">Mesocricetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067759" MajorTopicYN="N">Receptor for Advanced Glycation End Products</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005719" MajorTopicYN="Y">gamma-Globulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008558" MajorTopicYN="Y">Melphalan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38180084</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2300392</ArticleId><ArticleId IdType="pii">266583</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>